SynthesisDrug design, development and therapy2015
The IL-17A G-197A and IL-17F 7488T/C polymorphisms are associated with increased risk of cancer in Asians: a meta-analysis.
Synthesis in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Alternative Combinations of IL17A Polymorphic Variants with the Variants of TNF, IL1B, IL6, and IL8 Proinflammatory Cytokines Genes in Uterine Leiomyoma.Bulletin of experimental biology and medicine · 2025Article
- IL-17F promotes osteoblastic osteogenesis via the MAPK/ERK1/2 signaling pathway.Experimental and therapeutic medicine · 2021Article
- [Relationship between interleukin-17A gene polymorphisms and the susceptibility to childhood asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Interleukins 17 and 23 in patients with gastric neoplasms.Scientific reports · 2016Article
- Prognostic Significance of Genetic Polymorphisms rs3819024 (A/G) of Interleukin-17A Gene and rs763780 (C/T) of Interleukin-17F Gene in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma.Contemporary clinical dentistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-17 (IL-17) is a family of emerged pro-inflammatory cytokines. The IL-17A and IL-17F are two important members of IL-17 family. Previous studies have shown that the functional IL-17A G-197A and IL-17F 7488T/C polymorphisms may contribute to susceptibility to cancer but the results were inconclusive. This meta-analysis was performed to determine the exact association between IL-17 polymorphisms and cancer risk.
methodsOnline databases were searched to identify eligible case-control studies. Pooled odds ratios (ORs) and confidence intervals (CIs) were calculated by fixed-effect models or random-effect models. Publication bias was detected by Egger's test and Begg's test.
resultsNine eligible case-control studies of IL-17A G-197A and seven studies of IL-17F 7488T/C, including 3,181 cases and 4,005 controls, were identified. Pooled analysis suggested the variant IL-17A-197A allele was associated with increased risk cancer (GA/AA vs GG, OR =1.27, 95% CI: 1.15, 1.41, P heterogeneity =0.374; and A vs G, OR =1.30, 95% CI: 1.17, 1.45, P heterogeneity =0.021). For IL-17F 7488T/C, the homozygote 7488CC genotype significantly increased risk of cancer (CC vs TC/TT, OR =1.36, 95% CI: 0.97, 1.91, P heterogeneity =0.875; and CC vs TT, OR =1.39, 95% CI: 1.03, 1.88, P heterogeneity =0.979), especially for gastric cancer.
conclusionThe variant IL-17A-197A allele and IL-17F 7488CC genotype were associated with increased risk of cancer, especially for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.